These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 6133940

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Involvement of different dopamine receptors in rat diphasic motility response to apomorphine.
    Vaccheri A, Dall'Olio R, Gandolfi O, Montanaro N.
    Psychopharmacology (Berl); 1986; 89(3):265-8. PubMed ID: 2873607
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A.
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiemetic specificity of dopamine antagonists.
    Niemegeers CJ.
    Psychopharmacology (Berl); 1982 Dec; 78(3):210-3. PubMed ID: 6130555
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Strain differences to the effects of apomorphine on Sidman avoidance response and motor activity in the Wistar and F344/DuCrj (Fischer) rats.
    Kuribara H.
    Yakubutsu Seishin Kodo; 1983 May; 3(1):29-35. PubMed ID: 6666376
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents.
    Ugale RR, Hirani K, Morelli M, Chopde CT.
    Neuropsychopharmacology; 2004 Sep; 29(9):1597-609. PubMed ID: 15100702
    [Abstract] [Full Text] [Related]

  • 16. Antagonism of apomorphine induced climbing: is it a valid model for neuroleptic activity?
    Wallach MB, Hedley LR, Peterson KE, Schulz CH.
    Proc West Pharmacol Soc; 1980 Sep; 23():93-8. PubMed ID: 6105667
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites.
    Herrera-Marschitz M, Ungerstedt U.
    Eur J Pharmacol; 1984 Feb 17; 98(2):165-76. PubMed ID: 6143675
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG, Downs DA, Meltzer LT, Wiley JN, Williams AE.
    J Pharmacol Exp Ther; 1989 Oct 17; 251(1):105-12. PubMed ID: 2571712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.